Member Since 1990

LEARN MORE

Stäubli Robotics is a leading global player in robotics, consistently delivering engineering as effective and reliable as our service and support.

Content Filed Under:

Industry:
N/A

Application:
N/A

Stäubli Robotics appoints new head of pharma and medical device

POSTED 07/23/2021

Stäubli announced that Olivier Cremoux has been appointed Deputy Head of Pharma and Medical Device for Stäubli Robotics North America.

Cremoux joined Stäubli Group in 2015 before transferring to Stäubli Corporation as the North American Business Development Manager for Robotics in 2018. Most recently, he became Key Account Manager – Pharma and will maintain this role throughout the transition period.  Cremoux will use his experience to help build the Medical Robotics team while focusing on the Pharma and Medical Device specific markets.

Cremoux graduated from the National Institute of Science Applied of Lyon (France) with a bachelor degree in Electrical Engineering.

Commenting on the announcement, North American Robotics Division Manager, Sebastien Schmitt stated, “We are pleased to announce Mr. Cremoux as Stäubli Robotics North American Deputy Head of Pharma and Medical Device. We believe Mr. Cremoux is the right leader for Pharma and Medical Device as we continue to expand our growing team.  This is an important step in setting up an organization fully dedicated to the pharmaceutical industry to build on our existing expertise in a number of high?tech markets.”

Olivier Cremoux: “I am honored by such an opportunity within Stäubli Robotics.  Pharma and Medical Device are strategic and growing markets in which Stäubli has provided, for over 20 years, significant technological innovations.  High throughput screening, aseptic fill/finish, orthopedic surgery, bio-printing and cell culturing are examples of processes where Stäubli Robotics started as a pioneer and became a reference. With COVID-19 pandemic, robotics became even more essential to our customers, from drug production to Covid test manufacturing.  In North America, we will continue the development of our organization to ensure all current and future needs of our customers.”